A clinical formulation indicated for HIV. Active components work to inhibit viral replication cycles to assist in preserving long-term immune system integrity.
Formulated to alleviate HIV-1 infection and target viral exposure to support immune health and mitigate the risk of infection in high-risk populations.
Mechanism of Action
The two drugs work together to block reverse transcriptase, the enzyme HIV uses to make copies of itself. By inhibiting this process, the medication stops the virus from replicating or establishing an infection after exposure.
Route of Administration
Oral
Onset Time
Steady state in 7–10 days
Duration
24 hours
Contraindications
Pre-existing HIV infection (if used for PrEP only), Severe kidney impairment, Hypersensitivity to components
Severe Adverse Events
Lactic acidosis, Severe liver injury, Kidney failure, Worsening of Hepatitis B upon stopping, Immune reconstitution syndrome
Common Side Effects
Headache, Abdominal pain, Loose stools
Uncommon Side Effects
Nausea, Weight loss, Fatigue, Dizziness, Bone density loss
Information for Tenofovir Emtricitabine is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
